Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- EPS Gives 400 Workers CDISC Training to Set Itself Apart from Rival CROs
November 28, 2014
- MSD, Kyorin to Comarket Allergy Drug Desloratadine in Japan
November 28, 2014
- Novartis Files for Japan Approval of Equa-Metformin Combination Drug
November 28, 2014
- Kyowa Kirin Launches Sustained-Duration G-CSF Product G-Lasta
November 28, 2014
- Daiichi Sankyo Aims for No. 1 with Lixiana in Novel Oral Anticoagulant Market: Sales Division Head
November 28, 2014
- Allergan Targeting 10 Billion Yen Sales for GlashVista in Japan Eyelash Care Market
November 28, 2014
- ASKA Aims for 50% Share of Generic Candesartan Market through Blopress AG: President
November 27, 2014
- Janssen Files NDA for Anticancer Agent Ibrutinib in Japan
November 27, 2014
- Oncolys Files IND Application for Novel Cancer Treatment OBP-801 in US
November 27, 2014
- Kaken Banking on Clenafin to Boost Dermatology Biz
November 27, 2014
- Bulk Antibody Production Efficiency Up 10-fold, Production Costs Down “Several-fold” Since 2002: Chugai
November 26, 2014
- Amgen Calls Off Clinical Studies of Rilotumumab for Gastric Cancer
November 26, 2014
- MSD to Ensure Appropriate Use of Insomnia Drug Belsomra
November 26, 2014
- Eisai Launches Halaven in Brazil
November 26, 2014
- Eisai Launches Fycompa in Hong Kong
November 26, 2014
- MSD Seeks Japan Regulatory Approval for Once-Weekly DPP-4 Inhibitor
November 25, 2014
- Rushed Settlements Dragged Down Drug Delivery Prices: Vital KSK Exec
November 25, 2014
- Merck Serono Transfers Marketing Rights for Saizen to Fujifilm Pharma
November 25, 2014
- Top Two Japan Universities to Offer Undergrads Amgen-Sponsored Lab Experience Programs
November 21, 2014
- Domestic Subgroup Analysis Confirms Efficacy of Cimzia: Astellas, UCB Japan
November 21, 2014
ページ
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…